Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. - Wikidata - wikimedia - TriplyDB

Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

http://www.wikidata.org/entity/Q34243372

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Nano polymeric carrier fabrication technologies for advanced antitumor therapy Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice Rational combinations of immunotherapeutics that target discrete pathways.Monoclonal TCR-redirected tumor cell killing.Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.Spleen cells from young but not old immunized mice eradicate large established cancers.How to improve the immunogenicity of chemotherapy and radiotherapy.Is antigen specificity the key to efficient adoptive T-cell therapy?Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Therapeutic cancer vaccines: a long and winding road to success.Oncolytic viruses: a new class of immunotherapy drugs.Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.Dendritic Cells and Cancer Immunity.MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer.A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.Optimizing the immune system to achieve control of the metastatic malignant lesion.TNF-α-dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma.Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.Immunology: Cross-dressers turn on T cells.Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes.The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells.Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.

P2860

Q21131200-0F50C9D3-83A4-4EA3-9AF3-CF0B82681484 Q28393168-51EF5776-3303-4BA0-9EC8-F937B5BBB1B0 Q30399332-A2179156-6A49-4288-9935-71E276EA246D Q33606144-4FFD1BB8-CA41-4E5C-B150-69DCA9C57ACC Q34273053-30149F6B-B526-459B-AE18-7930E597F831 Q34370215-05A0ACCB-C1B4-45FB-92F9-586EABBEA7C4 Q35001971-E47D0BA0-2726-46A5-88EB-234BAA881BBF Q35024484-63DB5D61-258E-4813-ADC7-A7E08ABFA57C Q35071850-0116B739-7241-4885-BFAF-E5A325D92C66 Q35107009-228F36C1-AD3E-4857-AE99-B0C75D61B338 Q35570260-E0A2BF07-40B5-46FB-A82B-7C6B7E82F2E0 Q36173500-CA9FE3A2-E53B-46EA-89C6-1E8A6CA16DDB Q36249440-B7513FBE-3516-4F71-A8D3-B16D43F83C32 Q36349514-B7DDD2D1-A8FA-44D6-B8FC-6C07F52DF370 Q36558375-5F061375-D184-468E-A8A9-51CB1EBFCEB9 Q37078985-6C0F750A-C681-40F2-A415-3AEE8F165826 Q37706396-B8CE7745-01A5-4C91-B26D-B0E3DEE50AAE Q37836489-E58871D0-212B-41EB-8A47-340DBD75BBDD Q37861214-DEDD0C82-0A6B-4DE6-BCE0-B5A765612D72 Q37991701-29718C72-2C63-4799-AFDE-675566260C31 Q38060734-4C5D00B6-9161-4A3F-946C-74D62B9CAEE8 Q38162261-402B7879-8F81-4744-8368-B384AFAB4304 Q38577450-F81F815C-FAC1-4FD4-8F36-6D915811DBA4 Q38700706-594FB694-D574-4C0A-AFEB-46522C209BFD Q38994017-51A5EEC7-6F26-4B7C-9FC4-B147BEC2D11B Q39290133-1E35C336-FDBE-4ADA-AFEE-2305DEA61AE2 Q39414393-14C6FDCD-7EBC-4282-AF93-A989F2EEBB21 Q40877959-950F795E-F396-4FC5-AF7D-788B1E3005E5 Q40887427-AAD5F54C-3D2B-47EB-8D1B-5173C6CD87AB Q41891271-2C97EB31-97C9-48F8-AA26-2EFF5BF72AD0 Q42008502-81FECC4F-440B-40C0-B643-23FCB240D84E Q42028897-C8B0122A-43DA-44FB-9B8A-593137D55728 Q42362935-B63724C6-DC3A-4F6F-B639-C0F37DA330DE Q42573824-891B0D4C-367B-45D0-BA7B-7856D714A71E Q43227647-D38B691D-27CB-435A-B99F-908CC8DF1798 Q46604950-EB94AFF0-BA40-4CDD-BA35-B83D6149C0AA Q47794460-BCB59EEB-C144-4976-9299-09554747E514 Q47809269-7A7A6EB3-7E48-48EE-8649-94EFDD6A9FB9 Q48120406-E7F8D822-68EF-411E-B5FC-C04CDEDF3FC3 Q48185876-51561758-A1E6-4B5D-A276-8E80854C0FD0

P2860

Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

http://www.wikidata.org/entity/Q34243372

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Bystander killing of cancer requires the cooperation of CD4

@nl

Bystander killing of cancer re ...... lls during the effector phase.

@ast

Bystander killing of cancer re ...... lls during the effector phase.

@en

type

label

Bystander killing of cancer requires the cooperation of CD4

@nl

Bystander killing of cancer re ...... lls during the effector phase.

@ast

Bystander killing of cancer re ...... lls during the effector phase.

@en

prefLabel

Bystander killing of cancer requires the cooperation of CD4

@nl

Bystander killing of cancer re ...... lls during the effector phase.

@ast

Bystander killing of cancer re ...... lls during the effector phase.

@en

P1433

Q34243372-FDF88A43-F7D5-4A8D-8F92-6E555571A045

P1476

Q34243372-7AEEE804-AB91-4FF1-891D-3A0496E3FDAA

P2093

Q34243372-5A62B811-EDF5-4C94-A89A-C9DCDC9A613E

Q34243372-998002AB-8333-42EB-87A8-AF5DB0F3204E

Q34243372-9C539F17-4E86-4AC5-BC7A-05BEFC8AEA17

Q34243372-DEFBF296-5847-4537-990E-5F47A5988643

Q34243372-E8E03A84-7DD0-4D56-B8E2-3A1C8D0A95D0

P2860

Q34243372-01DF576E-7D8B-49D1-89C1-F807612613AD

Q34243372-074806D8-046B-4ACC-8217-9C215DDBF2D7

Q34243372-0B5FEC07-D24D-4E30-8F51-43D79CFDA60F

Q34243372-16868CA2-FF4A-4856-A4E8-88D6AB1C1DB4

Q34243372-2436D93D-7808-48D1-A054-9327B8B9162F

Q34243372-349CAD95-4FBB-4E10-8E9D-93BC26A3043F

Q34243372-358C3E9D-78FC-4546-AAD5-9DFD5F617151

Q34243372-3C7CD09E-E0DD-44B3-BB67-21FDDADBB75F

Q34243372-467F4139-0F6D-49B7-956F-0E5F8B4E3267

Q34243372-4CE674BB-C989-40E6-9DFE-171306B50EB3

P304

Q34243372-BE922128-AB28-4B71-8236-6AAB7695039E

P31

Q34243372-1DEB02C1-7AF2-4258-B053-CAE11E258EEF

P356

Q34243372-D0334098-0B05-498D-984A-257A56833B99

P407

Q34243372-D3D2838D-1F41-4919-BA9A-8411C4D9DEE3

P433

Q34243372-AB024A10-C8FD-4137-AE09-AECE795EFC30

P478

Q34243372-80D80985-5043-472A-B7BE-9E75EBE5E7A2

P577

Q34243372-5AD2163E-7625-4FB8-9F80-B8A786BC3575

P5875

Q34243372-5770DAC0-4FDA-4CED-B43A-D9D8F6E81487

P698

Q34243372-32B76D4F-6EBC-4D3B-B268-41CE6EAF02B0

P932

Q34243372-CA2C6B93-C6FB-4F83-9591-B8ED88A8D698

P356

P1433

Journal of Experimental Medicine

P1476

Bystander killing of cancer re ...... lls during the effector phase.

@en

P2093

Andrea Schietinger

http://www.w3.org/2001/XMLSchema#string

Hans Schreiber

http://www.w3.org/2001/XMLSchema#string

Karin Schreiber

http://www.w3.org/2001/XMLSchema#string

Mary Philip

http://www.w3.org/2001/XMLSchema#string

Rebecca B Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor-specific Th17-polarized cells eradicate large established melanoma

A unique tumor antigen produced by a single amino acid substitution

Production of high-titer helper-free retroviruses by transient transfection

Molecular characterization of the tumor microenvironment in breast cancer.

Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Loss of mismatched HLA in leukemia after stem-cell transplantation.

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

CD4 cells can be more efficient at tumor rejection than CD8 cells

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

P304

2469-2477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20092450

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

207

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47336487

http://www.w3.org/2001/XMLSchema#string

P698

20921286

http://www.w3.org/2001/XMLSchema#string

P932

2964573

http://www.w3.org/2001/XMLSchema#string